In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Protagonist Therapeutics Inc. Trade Record

NASDAQ:PTGX Protagonist Therapeutics Inc stock gains 7.13% Exit Jul 22, 2019 a Trade Record by priceseries

Trade Chart
Trade Chart PTGX Jun 27, 2019, priceSeries
About Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. Its product candidates include PTG-100, which has first-in-class potential as an oral, a4b7 integrin-specific antagonist peptide for the treatment of inflammatory bowel disease (IBD); PTG-200, a gastrointestinal-restricted peptide product candidate for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic peptide for the treatment of iron overload disorders, such as transfusion-dependent b-Thalassemia, hereditary hemochromatosis, and sickle cell disease. The company was founded in 2006 and is headquartered in Milpitas, California.

Trade Information
Trade Type
LONG
ReliabilityScore™
94.87
Entry Date
Jun 27, 2019
Entry Price
11.98
Sell Date
Jul 22, 2019
Sell Price
12.83
Net Gain
7.13%
Hold Time
16 Trading Days